{
    "clinical_study": {
        "@rank": "1519", 
        "arm_group": {
            "arm_group_label": "chlchicine treated patients", 
            "arm_group_type": "Experimental", 
            "description": "2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial"
        }, 
        "brief_summary": {
            "textblock": "This trial is to evaluate the potential of colchicine for the palliative management of\n      hepatocellular carcinoma patients with distant metastasis or large vessel invasion using the\n      Department of Health R.O.C. approved doses and methods of administration."
        }, 
        "brief_title": "Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Metastasis", 
            "Invasion"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Neoplasm Metastasis", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. . Patient has at least one of the following criteria: (1) positive for hepatocellular\n             carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level > 400\n             ng/mL and has evidence of hepatocellular carcinoma provided by contrast-enhanced\n             computed tomography or magnetic resonance imaging.\n\n          2. . Contrast-enhanced computed tomography or magnetic resonance imaging has evidence of\n             distant metastasis or large vessel invasion caused by hepatocellular carcinoma.\n\n          3. . Patient has Child A hepatic reserved function\n\n        Exclusion Criteria:\n\n          1. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and\n             hemorrhage from other vital organs such as lungs or brain.\n\n          2. . There are life-threatening bacterial, fungal or viral infection (not included\n             hepatitis B and C virus).\n\n          3. . Patient has serum creatinine level > 1.5 mg/dL.\n\n          4. . Patient must receive long-term medication of statin or fibrates drugs and these\n             medications can not be changed.\n\n          5. . Patient has white blood cell count < 1500/\u00b5L, platelet count < 30000/\u00b5L or\n             hemoglobin < 9.0 gm/dL after medication.\n\n          6. . Pregnant woman or plan to be a pregnant woman\n\n          7. . allergy to colchicine or has history of severe side effects caused by colchicine\n\n          8. . Patient has received systemic chemotherapy within 2 months before enrollment or\n             plans to receive systemic chemotherapy in the future.\n\n          9. . Patient is under or plans to receive Nexavar or other clinical trial testing drug.\n\n         10. . Patient has severe malfunction of vital organs and can not participate in this\n             study justified by the doctor in this research team.\n\n         11. . Patient is under or plans to receive Chinese traditional medicine or herb drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935700", 
            "org_study_id": "2013-04-03(I)"
        }, 
        "intervention": {
            "arm_group_label": "chlchicine treated patients", 
            "description": "Adjustment the dosage of colchicine during study:\nThe colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day.", 
            "intervention_name": "Colchicine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Colchicine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hepatocellular carcinoma", 
            "colchicine"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "contact": {
                "email": "linzuyau@yahoo.com.tw", 
                "last_name": "Z Y Lin, MS", 
                "phone": "886-7-323-4553"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung", 
                    "country": "Taiwan", 
                    "zip": "807"
                }, 
                "name": "Kaohsiung Medical University Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Zu Y Lin, MS", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "W L Chuang, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "M L Yu, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "S C Chen, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "C Y Dai, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "M L Yeh, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "J F Huang, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "M Y Hsieh, MS", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion", 
        "overall_contact": {
            "email": "linzuyau@yahoo.com.tw", 
            "last_name": "Zu Y Lin, MS", 
            "phone": "886-7-323-4553"
        }, 
        "overall_official": {
            "affiliation": "Kaohsiung Medical University", 
            "last_name": "Zu Y Lin, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The one year overall survival of the participants will be compared with the control group with the same TNM and the Barcelona Clinic Liver Cancer (BCLC) staging collected from 2005/1/1 to the end of this study.", 
            "measure": "overall survival", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "reference": {
            "PMID": "23871804", 
            "citation": "Lin ZY, Wu CC, Chuang YH, Chuang WL. Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci. 2013 Sep 3;93(8):323-8. doi: 10.1016/j.lfs.2013.07.002. Epub 2013 Jul 16."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935700"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
            "investigator_full_name": "Zu-Yau Lin", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kaohsiung Medical University Chung-Ho Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}